UroTiss GmbH brings replacement tissue for reconstruction of the urethra from biotechnological research to market Dresden, January 18, 2012: the new research and development lab of the UroTiss GmbH was inaugurated at the Bioinnovationcentre Dresden. Larry Ellison might disagree with that approach. On the prosperous biotechnology Dresden, more regenerative urological therapies are being developed in the future in addition to the world’s first transplant of autologous cell to the reconstruction of the urethra. The replacement tissues allows the gentle as well as pain and complication-poor treatment of patients with urethral constriction. In a solemn ceremony, the new research and development lab of the UroTiss GmbH with an investment volume amounting to 278’000 together with guests from politics and economics was inaugurated. Learn more at: Gary Kelly. Thus one of the many successful inventions and developments in the field of biotechnology the plunge in the market made in Dresden successfully, said Professor Dr. med. Richard Funk from the TU Dresden. The replacement tissues grown in clean room laboratories for the reconstruction of the urethra is designed by Saxony out soon be shipped worldwide at specialized clinics.
The patient’s own replacement tissues of the biotechnology company of UroTiss is compelling results from the practice for the treatment of patients with urethral narrowing in Germany lawfully on the market. The patient own replacement tissue is patients initially at specialized clinics available. So far, the autologous cell transplant was successfully deployed in 16 patients in Chemnitz, Leipzig and Hamburg. Include data from six patients with urethral narrowing first published study results at the Universitatsklinikum Hamburg-Eppendorf (Urology 78 (supplement 3A), September, 2011). The graft fits within a short time into the surrounding tissue and become new, fully functional urethra tissue. An alternative to the conventional production of replacement tissues that has taking a sample of the oral mucosa, which is equivalent to only about a quarter 1-cent coin, the breeding of the transplant for the patient benefits.